<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017870</url>
  </required_header>
  <id_info>
    <org_study_id>KSR-001-P01</org_study_id>
    <nct_id>NCT05017870</nct_id>
  </id_info>
  <brief_title>[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kukje Pharma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kukje Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic&#xD;
      characteristic of KSR-001.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After single dose, safety and local tolerability were confirmed and repeated test was&#xD;
      conducted according to the investigator's judgment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2018</start_date>
  <completion_date type="Actual">January 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>6 days</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>6 days</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>6 days</time_frame>
    <description>Pharmacokinetic Characteristics</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>KSR-001-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received KSR-001-01 for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KSR-001-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received KSR-001-02 for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KSR-001-03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received KSR-001-03 for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KSR-001-04</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received KSR-001-04 for 6 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSR-001</intervention_name>
    <description>(0 day) eye drops received one drop to both eyes once a day (1~5 day) eyedrops recieved one drop to both eyes four times a day</description>
    <arm_group_label>KSR-001-01</arm_group_label>
    <other_name>KSR-001-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSR-004</intervention_name>
    <description>(0 day) eye drops received one drop to both eyes once a day (1~5 day) eyedrops recieved one drop to both eyes four times a day</description>
    <arm_group_label>KSR-001-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSR-001-02</intervention_name>
    <description>KSR-001-02</description>
    <arm_group_label>KSR-001-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSR-001-03</intervention_name>
    <description>KSR-001-03</description>
    <arm_group_label>KSR-001-03</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male aged between 19 and 45 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          2. Body weight &gt;= 50 kilogram and ideal body weight within the range Â±20%.&#xD;
&#xD;
          3. Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject who has symptoms of suspected acute disease at the time of screening.&#xD;
&#xD;
          2. Subjects with a history of abnormal digestive organ, kidney, respiratory,&#xD;
             neuroendocrine, cardiovascular, hemato-oncology, urinary, musculoskeletal, immune, the&#xD;
             nose and ears, psychiatry, stomach system.&#xD;
&#xD;
          3. A subject determined to be unsuitable as a subject through a physical examined during&#xD;
             screening.&#xD;
&#xD;
          4. A subject who is determined to be unsuitable as a subject through an ophthalmologic&#xD;
             examination performed during screening.&#xD;
&#xD;
          5. A subject with a history of ophthalmic surgery, trauma and chronic diseases.&#xD;
&#xD;
          6. A subject who has acute or chronic eye disease requiring the use of local eye drops at&#xD;
             the time of screening.&#xD;
&#xD;
          7. Subjects who need to wear contact lenses during clinical trial period.&#xD;
&#xD;
          8. A subject with clinically significant allergic disease.&#xD;
&#xD;
          9. A subject with a history of drug abuse.&#xD;
&#xD;
         10. History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator&#xD;
             contraindicates their participation.&#xD;
&#xD;
         11. The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 90 days of the biological effect of the investigational product (whichever is&#xD;
             longer).&#xD;
&#xD;
         12. A subject who takes drugs that induce and inhibit drug metabolises such as barbital&#xD;
             medicines within one month before the administration of clinical trial drugs.&#xD;
&#xD;
         13. A subject who donates blood to the whole blood within 60 days before the&#xD;
             administration of a clinical trial drug or a person who donates blood to the component&#xD;
             within 20 days before the administration of a clinical trial drug.&#xD;
&#xD;
         14. A subject who has taken a specialty drug or herbal medicine within 14 days of&#xD;
             administration of a clinical trial drug or a general medicine or vitamin formulation&#xD;
             within 7 days.&#xD;
&#xD;
         15. A subject who can not continually ingest caffeine or ingest caffeine-containing foods&#xD;
             during the period from 24 hours to discharge from hospital.&#xD;
&#xD;
         16. A subject who can not drink alcohol continuously or during the period from 24 hours to&#xD;
             discharge from hospital.&#xD;
&#xD;
         17. A subject who can not smoke excessively or quit smoking during the period from 24&#xD;
             hours to discharge from hospital.&#xD;
&#xD;
         18. A subject who investigator that a tester is unsuitable for participating in clinical&#xD;
             trials due to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kukje Pharma</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

